Format

Send to

Choose Destination
Eur J Intern Med. 2017 Dec;46:66-70. doi: 10.1016/j.ejim.2017.08.013. Epub 2017 Sep 1.

Repetitive 18F-FDG-PET/CT in patients with large-vessel giant-cell arteritis and controlled disease.

Author information

1
Department of Internal Medicine, Caen University Hospital, France; University of Caen - Basse Normandie, Caen, France. Electronic address: deboysson-h@chu-caen.fr.
2
Department of Nuclear Medicine, Caen University Hospital, France; INSERM U1086 «ANTICIPE», BioTICLA, François Baclesse Cancer Centre, Caen, France. Electronic address: aide-n@chu-caen.fr.
3
Department of Internal Medicine, Limoges University Hospital, Limoges, France. Electronic address: eric.liozon@chu-limoges.fr.
4
Department of Internal Medicine, Lille University Hospital, France. Electronic address: marc.lambert@chru-lille.fr.
5
Biostatistics and Clinical Research Unit, Caen University Hospital, France. Electronic address: parienti-jj@chu-caen.fr.
6
Department of Nuclear Medicine, Limoges University Hospital, France. Electronic address: Jacques.monteil@chu-limoges.fr.
7
Department of Nuclear Medicine, Lille University Hospital, France. Electronic address: Damien.huglo@chru-lille.fr.
8
Department of Internal Medicine, Caen University Hospital, France; University of Caen - Basse Normandie, Caen, France. Electronic address: bbienvenu@hopital-saint-joseph.fr.
9
Department of Nuclear Medicine, Caen University Hospital, France; Normandie Université EA4650, Caen, France. Electronic address: manrique@cyceron.fr.
10
Department of Internal Medicine, Caen University Hospital, France; University of Caen - Basse Normandie, Caen, France. Electronic address: aouba-a@chu-caen.fr.

Abstract

OBJECTIVE:

18F-FDG PET/CT can detect large-vessel involvement in giant-cell arteritis (GCA) with a good sensitivity. In patients with clinically and biologically controlled disease, we aimed to assess how vascular uptakes evolve on repetitive FDG-PET/CT.

PATIENTS AND METHODS:

All included patients had to satisfy the 4 following criteria: 1) diagnosis of GCA was retained according to the criteria of the American College of Rheumatology or based on the satisfaction of 2 criteria associated with the demonstration of large-vessel involvement on FDG-PET/CT; 2) all patients had a positive PET/CT that was performed at diagnosis before treatment or within the first 10days of treatment; 3) another FDG-PET/CT was performed after at least 3months of controlled disease without any relapse; 4) patients were followed-up at least for 12months.

RESULTS:

Twenty-five patients (17 [68%] women, median age: 69 [65-78]) with large-vessel inflammation on a baseline FDG-PET/CT and with repetitive imaging during the period with controlled disease were included and followed-up for 62 [25-95] months. Four repeated procedures revealed total extinction of vascular uptakes at 11.5 [8-12] months after the first FDG-PET/CT. Eight PET/CT revealed decreased numbers of vascular uptakes, and 10 procedures revealed no changes. The 3 remaining procedures indicated worsening of the numbers of vascular uptakes in the absence of relapse.

CONCLUSIONS:

Our study revealed long-term persistent vascular uptake on repeated FDG-PET/CT in >80% of our GCA patients with large-vessel inflammation and clinical-biological controlled disease. Prospective studies are required to confirm these findings.

KEYWORDS:

FDG-PET/CT; Giant-cell arteritis; Large-vessel involvement; Repetitive imaging

PMID:
28865740
DOI:
10.1016/j.ejim.2017.08.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center